FIRAZYR: FDA Approved Drugs and User Comments

User Comments:

For Hereditary Angioedema “This does not really work. With a throat attack it provides some relief. Even after I have taken the drug with one attack I will still get another attack within an hour of taking the drug. It doesn’t stop or reduce swelling in any part of my body especially my face. If I take the shot for one eye it will continue to swell and the other eye begins to swell and that’s after a second shot. I’m not sure how well it works for other but for me it is useless.”

Anonymous (taken for 1 to 6 months) August 24, 2017

For Hereditary Angioedema “I am an unusual case in that I started experiencing attacks before I could walk. I swell more frequently and severely than any other member of my considerably large family. Unfortunately, Firazyr has provided minimal relief. It has slowed the onset of swelling, but did not stop it all together. That being said, I am grateful for any relief I can get during an attack, so I would encourage everyone to try Firazyr to treat their own episodes.”

SwellMom (taken for 1 to 2 years) March 30, 2015

For Hereditary Angioedema “Dealing with Hereditary Angioedema since I’ve been 12, now 40. This is a God send! Works great for me and my brother, pain and swelling quickly dissipates depending on attack. My sister tried it, but not her favorite due to burning she gets..we haven’t experienced anything other that a little redness! This is one small step in helping us deal with this disease. “

CoachDriver June 23, 2013

For Hereditary Angioedema “Firazyr stopped the swelling from HAE and also reduced the swelling within about 45 minutes. The sooner you treat with Firazyr, at the onset of symptoms, the better the result.”

Anonymous (taken for 1 to 2 years) December 10, 2012

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.